NHS Western Isles Dispenses Weight Loss Drugs at Three Times Scottish National Rate
NHS Western Isles has been identified as prescribing glucagon-like peptide-1 (GLP-1) receptor agonists, primarily Ozempic, at three times the national average across Scotland. Data from Public Health Scotland indicates that for every 1,000 residents in the Outer Hebrides, 21.9 prescription items for these weight loss drugs were issued in the last year, compared to the Scottish average of 7.1 per 1,000.
The report from Public Health Scotland also highlighted a "significant variation" in the uptake of new medicines across different health boards, with notable differences observed in the prescribing of drugs for conditions such as diabetes and heart failure. This inconsistency means patients' access to newer treatments can depend heavily on their geographical location within Scotland.
GLP-1 receptor agonists are primarily licensed for type 2 diabetes but are also used off-label for weight management. The escalating demand for these medications has led to supply issues, prompting warnings from the Medicines and Healthcare products Regulatory Agency (MHRA) against their off-label use for obesity due to shortages impacting diabetic patients.
While NHS Western Isles attributes its higher prescribing rates to robust local initiatives addressing chronic conditions, the broader implications of such disparities in healthcare provision remain a critical concern. These variations underscore the ongoing challenge of ensuring equitable and consistent access to medicines across the country, prompting questions about the criteria and oversight of prescribing practices.
